Abstract: A mixed chemistry battery including a sensing cell having a first chemistry, a battery cell having a second chemistry that is different than the first chemistry. The mixed chemistry battery also includes a sensor configured to measure a temperature of the mixed chemistry battery and a heating system configured to heat the second battery cell. The mixed chemistry battery further includes a battery monitoring system configured to selectively connect the heating system to at least one of the first battery cell and the second battery cell based upon the temperature of the mixed chemistry battery.

Abstract: Provides are a drive method of a display panel and a display apparatus. The drive method of the display panel includes: obtaining a current temperature of the display panel; obtaining a current overdrive lookup table corresponding to the current temperature according to the current temperature and initial overdrive lookup tables corresponding to prestored set temperatures, wherein the initial overdrive lookup tables include a plurality of different first gray-scale values, a plurality of different second gray-scale values and initial gray-scale values corresponding to any first gray-scale value and any second gray-scale value, and the current overdrive lookup table includes a plurality of different first gray-scale values, a plurality of different second gray-scale values and current gray-scale values corresponding to any first gray-scale value and any second gray-scale value; and driving sub-pixels in the display panel to charge corresponding data voltages according to the current overdrive lookup table.

Abstract: Provides are an ultrasonic transducer, a fabrication method thereof and an electronic device. The ultrasonic transducer includes: an array substrate having a groove, a bottom electrode and an insulation layer, wherein an orthographic projection of the groove on the array substrate is within an orthographic projection of the bottom electrode on the array substrate, and the insulation layer covers the bottom electrode; and an opposite substrate, the opposite substrate and the array substrate are oppositely arranged and are attached to each other, the opposite substrate and the array substrate form a cavity in the groove, the opposite substrate has a top electrode and a vibrating diaphragm layer which are arranged in stack, and an orthographic projection of the top electrode on the array substrate is within the orthographic projection of the bottom electrode on the array substrate.

Abstract: A device (14) for fusing sensor data with map data, includes: an input interface (24) for receiving sensor data of a surroundings sensor (18) with information regarding objects in the surroundings of a vehicle (12) and for receiving map data with information regarding the vehicle surroundings; an evaluation unit (26) for recognizing visible traffic signs (20) in the vehicle surroundings on the basis of the sensor data and for reading out known traffic signs in the vehicle surroundings from the map data; and an assignment unit (28) for assigning the visible traffic signs to the known traffic signs and for determining a certainty parameter which indicates a probability of a correct assignment.

Abstract: A device (14) for fusing sensor data with map data, includes: an input interface (24) for receiving sensor data of a surroundings sensor (18) with information regarding objects in the surroundings of a vehicle (12) and for receiving map data with information regarding the vehicle surroundings; an evaluation unit (26) for recognizing visible traffic signs (20) in the vehicle surroundings on the basis of the sensor data and for reading out known traffic signs in the vehicle surroundings from the map data; and an assignment unit (28) for assigning the visible traffic signs to the known traffic signs and for determining a certainty parameter which indicates a probability of a correct assignment.

Abstract: Methods and systems for a unified application notification framework are described herein. A server may receive a notification from a service provider. The service provider may be associated with an application executable on a virtual machine. The virtual machine may be part of a virtual environment that includes a user interface. The server may determine an identifier for the received notification. The identifier may indicate the application on the virtual machine associated with the service provider. The server may provide the received notification to the user interface for display to a user. The received notification may be displayed without execution of the application on the virtual machine.

Abstract: Methods and systems for a unified application notification framework are described herein. A server may receive a notification from a service provider. The service provider may be associated with an application executable on a virtual machine. The virtual machine may be part of a virtual environment that includes a user interface. The server may determine an identifier for the received notification. The identifier may indicate the application on the virtual machine associated with the service provider. The server may provide the received notification to the user interface for display to a user. The received notification may be displayed without execution of the application on the virtual machine.

Abstract: Methods and systems for a unified application notification framework are described herein. A server may receive a notification from a service provider. The service provider may be associated with an application executable on a virtual machine. The virtual machine may be part of a virtual environment that includes a user interface. The server may determine an identifier for the received notification. The identifier may indicate the application on the virtual machine associated with the service provider. The server may provide the received notification to the user interface for display to a user. The received notification may be displayed without execution of the application on the virtual machine.

Abstract: Use of antagonists to IL-31 are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.

Abstract: Use of antagonists to IL-31Ra and OSMRb are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include soluble receptors, antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.

Abstract: Use of antagonists to IL-31 are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.

Abstract: Use of antagonists to IL-31Ra and OSMRb are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include soluble receptors, antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.

Abstract: Use of antagonists to IL-31 are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.

Abstract: Use of antagonists to IL-31Ra and OSMRb are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include soluble receptors, antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.

Abstract: Disclosed are antagonists of PDGF receptor ? (PDGFR?) and VEGF-A, including neutralizing anti-PDGFR? and anti-VEGF-A antibodies, as well as related compositions and methods. Anti-PDGFR? and anti-VEGF-A antibodies disclosed herein include bispecific antibodies capable of binding and neutralizing both PDGFR? and VEGF-A. Also disclosed are methods of treating an neovascular disorder, such as cancer or an neovascular ocular disorder, using a PDGFR? and/or VEGF-A antagonist.

Abstract: Use of antagonists to IL-31 are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.

Abstract: Use of antagonists to IL-31Ra and OSMRb are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include soluble receptors, antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.

Abstract: Use of antagonists to IL-31 are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.

Abstract: Use of antagonists to IL-31Ra and OSMRb are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include soluble receptors, antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.

Abstract: Disclosed are antagonists of PDGF receptor ? (PDGFR?) and VEGF-A, including neutralizing anti-PDGFR? and anti-VEGF-A antibodies, as well as related compositions and methods. Anti-PDGFR? and anti-VEGF-A antibodies disclosed herein include bispecific antibodies capable of binding and neutralizing both PDGFR? and VEGF-A. Also disclosed are methods of treating an neovascular disorder, such as cancer or an neovascular ocular disorder, using a PDGFR? and/or VEGF-A antagonist.